Common Disease-Modifying Therapies for Multiple Sclerosis
The most commonly used disease-modifying therapies (DMTs) for MS include interferon-β (IFNβ1a and IFNβ1b), glatiramer acetate, oral agents (fingolimod, dimethyl fumarate, teriflunomide), and monoclonal antibodies (natalizumab, ocrelizumab, alemtuzumab, ofatumumab). These medications target the inflammatory component of relapsing-remitting MS (RRMS) and vary in efficacy and safety profiles 1.
First-Line Moderate-Efficacy DMTs
The traditional first-line agents include:
- Interferon-β preparations (IFNβ1a subcutaneous/intramuscular, IFNβ1b subcutaneous) - immunomodulators that reduce relapse rates 2, 3
- Glatiramer acetate - immunomodulator with moderate efficacy 2, 3
- Oral agents:
These medications can be administered at any time without specific timing restrictions, though they may attenuate vaccine responses 2.
High-Efficacy DMTs
For patients with more aggressive disease or those failing moderate-efficacy treatments:
- Fingolimod - sphingosine-1-phosphate receptor modulator, demonstrated superiority over placebo in reducing brain atrophy 4, 3
- Natalizumab - highly potent monoclonal antibody, one of the most effective for relapse prevention but carries PML risk requiring JC virus antibody monitoring 2, 1, 3
- Ocrelizumab - anti-CD20 monoclonal antibody, superior to IFNβ1a in reducing brain atrophy, also approved for primary progressive MS 4, 1
- Ofatumumab - anti-CD20 therapy, high-efficacy option 1, 3
- Alemtuzumab - immune-reconstitution therapy, highly efficacious but with considerable side effect profile including autoimmune complications 1, 4, 1
Immune-Reconstitution Therapies
These require specific timing considerations:
- Alemtuzumab and cladribine - vaccination should be delayed at least 6 months after the last treatment course 2
- Ocrelizumab - vaccination should occur 4-6 weeks before starting therapy or 4-6 months after the last infusion 2
Treatment for Progressive MS
For secondary progressive MS specifically:
- Siponimod - sphingosine-1-phosphate receptor modulator 3
- Ofatumumab - also indicated for secondary progressive forms 3
Critical Timing and Safety Considerations
When switching between DMTs, washout periods are essential - particularly after long-acting lymphodepleting agents like alemtuzumab or after multiple lines of therapy, to balance MS relapse risk against complications from treatment sequencing 1. However, washout should be kept as short as possible to avoid disease activity 1.
For patients on high-dose or long-term corticosteroids, these should be tapered below 20 mg prednisone equivalent daily, with treatment delayed 4-6 weeks after cessation before starting certain DMTs 2.
Common Pitfall
The "pseudoatrophy effect" occurs with many DMTs, particularly in the first 6-12 months of treatment, where brain volume loss appears to accelerate due to resolution of inflammatory edema rather than true neurodegeneration 4. This is seen with natalizumab, IFNβ, and other anti-inflammatory agents, and should not be misinterpreted as treatment failure.
Emerging Treatment Paradigm
Treatment strategy is shifting from the traditional "escalation approach" (starting with safer, moderate-efficacy drugs) toward an "early top-down strategy" using high-efficacy treatments first, based on individual prognostic factors 3. This personalized approach prioritizes efficacy while maintaining appropriate risk management, particularly for progressive multifocal leukoencephalopathy with natalizumab and autoimmune complications with alemtuzumab.